A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Healthy Volunteers
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Sequential AssignmentMasking: Triple (Participant, Care Provider, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 55 years
- Gender
- Both males and females
Description
This is the first-in-human study with BBP-671 and is designed to provide single- and multiple-dose safety, tolerability, PK, and PD data regarding BBP-671 for future clinical studies.
This is the first-in-human study with BBP-671 and is designed to provide single- and multiple-dose safety, tolerability, PK, and PD data regarding BBP-671 for future clinical studies.
Tracking Information
- NCT #
- NCT04836494
- Collaborators
- Not Provided
- Investigators
- Study Chair: Medical Monitor VP Clinical Development, CoA Therapeutics, Inc.
Get Well Soon